Blood test finds hidden targets: new hope for HER2-Negative breast cancer patients
NCT ID NCT01975142
First seen Dec 09, 2025 · Last updated May 18, 2026 · Updated 16 times
Summary
This study looked at 155 people with metastatic breast cancer whose original tumors were HER2-negative. Researchers checked their blood for cancer cells that had extra HER2 genes. If found, participants received the drug T-DM1. The goal was to see if these hidden HER2-positive cells could predict who would respond to treatment, offering a new option for patients who otherwise would not qualify for this therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER, HER2 NEGATIVE PRIMARY TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Catherine de Sienne
Vandœuvre-lès-Nancy, 54519, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre Val d'Aurelle - P. Lamarque
Montpellier, 34298, France
-
Chu Saint-Louis
Paris, 75475, France
-
Chu de Limoges
Limoges, 87042, France
-
Clinique Victor Hugo
Le Mans, 72000, France
-
Institut Curie
Paris, 75005, France
-
Institut Curie - Hôpital René HUGENIN
Saint-Cloud, SAINT-CLOUD, France
-
Institut de Cancérologie HARTMANN
Levallois-Perret, 92309, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, 54519, France
Conditions
Explore the condition pages connected to this study.